VIDEO: Belzutifan ‘has the chance to become a new standard-of-care’

ByToni K. Choueiri, MD

BySavannah Demko

Fact checked byMindy Valcarcel, MS

MADRID — Toni Choueiri, MD, talked with Healio about some of the new kidney cancer data “that could be practice-changing and, for sure, practice-informing” presented at ESMO Congress.

In this video interview, Choueiri, director of the Lank Center for Genitourinary Cancer at Dana-Farber Cancer Institute, discussed three presentations on belzutifan (Welireg, Merck):

the updated analysis of phase 2 LITESPARK-003 study on belzutifan plus cabozantinib for advanced clear cell RCC;
the phase 2 LITESPARK-013 study of two doses of belzutifan in patients with advanced RCC; and
the phase 3 LITESPARK-005 study of belzutifan versus everolimus in patients with previously treated advanced clear cell RCC.

Discussing the LITESPARK-005 study, Choueiri said that “this has the chance to become a new standard-of-care.”

References:

Albiges L, et al. Abstract LBA88. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Agarwal N, et al. Abstract 18810. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Choueiri TK, et al. Abstract LBA87. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.

Published by:

Sources/Disclosures

Collapse

Source: Healio Interviews

Disclosures: Choueiri reports numerous ties to industry.

Take Homes in Renal Cell Carcinoma

Read more

VIDEO: Belzutifan ‘has the chance to become a new standard-of-care’

Related Content